Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

ctive earnings, revenue and earnings growth, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements, including the statements contained herein regarding anticipated trends in the Company's business, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industries, the Company's ability to manage growth and continue to attract and retain qualified personnel, the Company's ability to complete additional acquisitions and to integrate newly acquired businesses, the Company's ability to penetrate new markets, the fixed price nature of contracts and cost overruns, the loss, cancellation or delay of contracts or amendments thereto, the ability to maintain existing customer relationships or enter into new ones, the Company's sales cycle, the Company's ability to obtain financing on terms acceptable to the Company, the effects of exchange rate fluctuations, risks related to non-US operations and other factors described in the Company's filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. No assurance can be given that the Company will be able to realize the net service revenues included in backlog and verbal awards. Kendle believes that its aggregate backlog and verbal awards are not necessarily a meaningful indicator of future results. All information in this release is current as of Nov. 4, 2008. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
(Date:7/31/2014)... people over 60 are not donor candidates for bone ... time, making the elderly prone to life-threatening infection and ... now has discovered a reason why. , "We have ... blood-forming cells to maintain blood production over time in ... could be restored for rejuvenation therapies," said Emmanuelle Passegu, ...
(Date:7/31/2014)... to see through organs and even the entire body ... fine-grained cellular structures has been a long-time dream of ... July 31st in the journal Cell has ... for making opaque organs, bodies, and human tissue biopsies ... The protocols could pave the way for a better ...
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
Breaking Biology Technology:Midwest Biotech Leaders Featured On BioSpace Map 2Key to aging immune system is discovered 2See-through organs and bodies will accelerate biomedical discoveries 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3
... , 3Q09 Corporate Highlights: , ... Europe Ltd. Made significant progress in commercial readiness ... Director, Marketing; and Director, Commercial Operations Appointed Bradford S. ... , Upcoming 2009 Milestones: , ...
... Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations ... exenatide) program for the treatment of type 2 diabetes ... Francisco, CA: , (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) , ... Lowers Plasma Glucose, HbA1c and Reduces Weight in a ...
... , GAITHERSBURG, Md., Nov. 5 GenVec, Inc. (Nasdaq: GNVC ... September 30, 2009. GenVec reported a net loss of $3.6 million ... compared to a net loss of $6.8 million ($0.08 per share) ... September 30, 2009, GenVec,s net loss was $14.1 million ($0.15 per ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
(Date:7/31/2014)... first-of-its-kind study of bigeye tuna movements in the northwestern ... Large Pelagics Research Center at the University of Massachusetts ... a wide geographical range with pronounced north-south movements from ... a high-use area off Cape Hatteras southwest of Bermuda ... new approach to study one of the most important ...
(Date:7/31/2014)... U.S. Census Bureau, Latinos are the largest minority group ... Approximately one-third of Latinos are obese and are ... non-Hispanic Whites. , NYU College of Nursing student ... to identify the factors that contribute to this problem ... focused on food patterns in Latina women recently published ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):Study of bigeye tuna in Northwest Atlantic uses new tracking methods 2Study of bigeye tuna in Northwest Atlantic uses new tracking methods 3NYU research looks to combat US Latina immigrant obesity 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... fever wax and wane over a period of several ... the incidence and range of the potentially deadly mosquito-borne ... has never been more important. , A new study ... a brief period of cross-immunity conferred by any one ...
... led by a conservationist from the Bronx Zoo-based Wildlife ... European Union project CURESS near Chad's Zakouma National Park, ... only their tusks -- a sure sign that poaching ... protected area. , Mike Fay, a WCS conservationist and ...
... genes with a single injection into a vein holds ... heart, University of Florida researchers report. , UF researchers ... with a form of muscular dystrophy that damages the ... monkeys and found genes were readily absorbed by heart ...
Cached Biology News:UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3Widespread elephant slaughter discovered in Chad 2UF scientists test improved gene therapy method for hereditary heart conditions 2UF scientists test improved gene therapy method for hereditary heart conditions 3UF scientists test improved gene therapy method for hereditary heart conditions 4
LIGHT DIAGNOSTICS Echovirus Blend Reagent, ~50 tests, included in kit #3340 & #3365...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
TRIAL SIZE Anti-Kaede [2F4] Monoclonal Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Phospho-C/EBPbeta (Thr235) Antibody...
Biology Products: